l Inombolo ye-Cas: 171596-29-5 I-Molecular Formula: C₂₂H₁₉N₃O₄
| I-Melting Point | > 193°C |
| Ukuminyana | I-DMF: 25 mg/ml I-DMF:PBS (pH 7.2) (1:1): 0.5 mg/ml I-DMSO: 20 mg/ml |
| izinga lokushisa lokugcina | -20°C |
| ukuncibilika | I-DMF: 25 mg/ml I-DMF:PBS (pH 7.2) (1:1): 0.5 mg/ml I-DMSO: 20 mg/ml |
| umsebenzi optical | [α]/D +68 kuya +78°, c = 1 ku-chloroform-d |
| Ukubukeka | Okuqinile Okumhlophe kuya Kokumhlophe |
| Ubumsulwa | ≥98% |
(igama lemakethe noma ) uhlobo lwe-PDE5 inhibitor esetshenziselwa ukwelapha ukungasebenzi kahle kwe-erectile, i-benign prostatic hypertrophy kanye ne-pulmonary arterial hypertension.Umphumela uwukuphumuza imisipha yemithambo yegazi nokwandisa ukugeleza kwegazi ku-corpus cavernosum.Indlela yokusebenza ye-inhibiting umsebenzi we-cGMP ethize phosphodiesterase hlobo 5 (PDE5).I-PDE5 yehlisa isithunzi i-cGMP ku-corpus cavernosum etholakala eduze komthondo.Ngakho-ke, i-tadalafi iholela ekwandeni kokuhlushwa kwe-cGMP okuphinde kubangele ukuphumula kwemisipha ebushelelezi kanye nokukhuphuka kwegazi ku-corpus cavernosum.Ezinye izifundo zomtholampilo ziphinde zasikisela ukuthi zingathuthukisa ukusebenza kwe-endothelia emadodeni anengozi eyandayo yenhliziyo nemithambo yegazi futhi ehlise izimpawu zepheshana lomchamo okwesibili ku-benign prostatic hyperplasia.
i-analgesic, i-uptake blocker, i-mu-opiod receptor agonist.I-phosphodiesterase 5 inhibitor.isetshenziselwa ukwelapha ukungasebenzi kahle kwe-erectile.
ihluke ngesakhiwo kusuka kokubili i-sildenafil ne-vardenafil.Imuncwa ngokushesha futhi inyuke kakhulu ekugxilweni kwayo (378 μg/L ngemva komthamo we-20-mg) ngemva kwamahora ama-2, ibonise isigamu sempilo ende yamahora angu-17.5.Iphinde isetshenziswe isibindi (CYP3A4).Ngokuphawulekayo, i-pharmacokinetics yayo ayithonywa ngokomtholampilo utshwala noma ukudla noma izinto ezifana nesifo sikashukela noma ukungasebenzi kahle kwesibindi noma izinso.
